GlassScriptPhysician profile
Carla M Molliner
NPI 1548225675
$8,908.46
in general payments reported to CMS, 2019-2025
14 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,251 · 2022: $2,234 · 2023: $2,895 · 2024: $1,126 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,266 · Consulting Fee: $800 · Travel and Lodging: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,265.88 |
| Consulting Fee | $800.00 |
| Travel and Lodging | $357.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,634.71 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Gilead Sciences, INC. | $1,257.15 | 2021-2025 | Epclusa |
| Intercept Pharmaceuticals, INC. | $716.81 | 2021-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $499.69 | 2024-2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $490.19 | 2023-2025 | Terlivaz |
| Abbvie INC. | $409.88 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $263.93 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $184.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Jazz Pharmaceuticals INC. | $146.69 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.71 | 2023 | |
| Boston Scientific Corporation | $89.28 | 2024 | Watchman Access System |
| Genentech USA, INC. | $50.03 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $25.04 | 2024 | Utaswako Afp-L3 |
| Dynavax Technologies Corporation | $16.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Molliner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.